<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from (a) the
Unaudited, Consolidated Financial Statements of Genzyme Corporation and
Subsidiaries for the three months ended March 31, 2000 and is qualified in its
entirety by reference to such, (b) financial statements as included in the Form
10-Q for Genzyme Corporation dated march 31, 2000.
</LEGEND>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-2000
<PERIOD-START> JAN-01-2000
<PERIOD-END> MAR-31-2000
<CASH> 112,194
<SECURITIES> 574,424
<RECEIVABLES> 186,967
<ALLOWANCES> 23,731
<INVENTORY> 117,991
<CURRENT-ASSETS> 712,030
<PP&E> 582,583
<DEPRECIATION> 195,740
<TOTAL-ASSETS> 1,916,042
<CURRENT-LIABILITIES> 145,725
<BONDS> 0
0
0
<COMMON> 1,421
<OTHER-SE> 1,475,398
<TOTAL-LIABILITY-AND-EQUITY> 1,916,042
<SALES> 205,387
<TOTAL-REVENUES> 208,130
<CGS> 48,259
<TOTAL-COSTS> 60,110
<OTHER-EXPENSES> 96,069
<LOSS-PROVISION> 4,340
<INTEREST-EXPENSE> 3,939
<INCOME-PRETAX> 43,672
<INCOME-TAX> 11,854
<INCOME-CONTINUING> 31,818
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 31,818
<EPS-BASIC> 0.61<F1>
<EPS-DILUTED> 0.57<F1>
<FN>
<F1>Genzyme Corporation reports earnings per share for each of its four series of
common stock. The earnings per share information presented on this schedule
represents the earnings per share data for net income attributable to Genzyme
General Stock. For the period presented, net income allocated to Genzyme
General was $51,637. For the period presented, net loss allocated to Genzyme
Molecular Oncology was $(5,057) or $(0.37) per basic and diluted share
of Molecular Oncology Stock, net loss allocated to Genzyme Surgical Products
was $(10,043) or $(0.68) per basic and diluted share of Surgical Products
Stock, and net loss allocated to Genzyme Tissue Repair was $(4,971) or
$(0.17) per basic and diluted share of Tissue Repair Stock.
</FN>
</TABLE>
